Home Research Staff Publications


Prof. Dr. Gerhard Gründer

Cumming P, Abi-Dargham A, Gründer G. Molecular imaging of schizophrenia: Neurochemical findings in a heterogeneous and evolving disorder. Behav Brain Res. 2021 398:113004.
Eap CB, Gründer G, Baumann P, Ansermot N, Conca A, Corruble E, Crettol S, Dahl ML, de Leon J, Greiner C, Howes O, Kim E, Lanzenberger R, Meyer JH, Moessner R, Mulder H, Müller DJ, Reis M, Riederer P, Ruhe HG, Spigset O, Spina E, Stegman B, Steimer W, Stingl J, Suzen S, Uchida H, Unterecker S, Vandenberghe F, Hiemke C. Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants. World J Biol Psychiatry. 2021 22(8):561-628. Epub 2021 May 12.
Gründer G. Psychedelics: A New Treatment Paradigm in Psychiatry?. Pharmacopsychiatry. 2021 54(4):149-150. Epub 2021 Jun 24..
Gründer G, Bauknecht P, Klingberg S, Leopold K, Paulzen M, Schell S, Stengler K, Leucht S. Treatment Goals for Patients with Schizophrenia - A Narrative Review of Physician and Patient Perspectives. Pharmacopsychiatry. 2021 54(2):53-59. Epub 2020 Dec 8.
Gründer G, Cumming P. Serotonin and amyloid deposition: A link between depression and Alzheimer's disease?: An Editorial Highlight on "Pimavanserin, a 5HT receptor inverse agonist, rapidly suppresses Aβ production and related pathology in a mouse model of Alzheimer's disease". J Neurochem. 2021 156(5):560-562. Epub 2021 Jan 18.
Gründer G, Jungaberle H. The Potential Role of Psychedelic Drugs in Mental Health Care of the Future. Pharmacopsychiatry. 2021 54(4):191-199. Epub 2021 May 12..
Gründer G, Mertens L. Psilocybin for Depression. N Engl J Med. 2021 385(9):863.
Kossmann C, Heller J, Brüne M, Schulz C, Heinze M, Cordes J, Mühlbauer B, Rüther E, Timm J, Gründer G, Juckel G. Assessment of Psychosocial Functioning in a Large Cohort of Patients with Schizophrenia. Psychiatr Q. 2021 29(1):177-191. Epub 2020 Jun 9.
Kuzin M, Haen E, Hiemke C, Bochon B, Bochon K, Gründer G, Paulzen M, Schoretsanitis G. Body mass index as a determinant of clozapine plasma concentrations: A pharmacokinetic-based hypothesis. J Psychopharmacol. 2021 35(3):273-278. Epub 2021 Feb 5.
Pfeifer P, Sebastian A, Buchholz HG, Kaller CP, Gründer G, Fehr C, Schreckenberger M, Tüscher O. Prefrontal and striatal dopamine D/D receptors correlate with fMRI BOLD activation during stopping. Brain Imaging Behav. 2021 Aug 17. [Epub ahead of print]
Schoretsanitis G, Baumann P, Conca A, Dietmaier O, Giupponi G, Gründer G, Hahn M, Hart X, Havemann-Reinecke U, Hefner G, Kuzin M, Mössner R, Piacentino D, Steimer W, Zernig G, Hiemke C. Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic Drugs. Ther Drug Monit. 2021 43(1):79-102. Epub 2020 Nov 4.
Schoretsanitis G, Haen E, Conca A, Piacentino D, Ridders F, Hiemke C, Gründer G, Paulzen M. Lack of Smoking Effects on Pharmacokinetics of Oral Paliperidone-analysis of a Naturalistic Therapeutic Drug Monitoring Sample. Pharmacopsychiatry. 2021 54(1):31-35. Epub 2020 Aug 6.
Schoretsanitis G, Haen E, Piacentino D, Conca A, Endres K, Carpi F, Hiemke C, Gründer G, Paulzen M. Pharmacokinetic Correlates of Once-Monthly Paliperidone Palmitate-Related Adverse Drug Reactions. Clin Pharmacokinet. 2021 Jun 18. [Epub ahead of print]
Schoretsanitis G, Haen E, Piacentino D, Conca A, Endres K, Hiemke C, Gründer G, Paulzen M. Clinical response in patients treated with once-monthly paliperidone palmitate: analysis of a therapeutic drug monitoring (TDM) database. Eur Arch Psychiatry Clin Neurosci. 2021 271(8):1437-1443. Epub 2021 Apr 5.

Zentralinstitut für Seelische Gesundheit (ZI) - https://www.zi-mannheim.de